The Clorox Company (NYSE:CLX) Stock Position Raised by Regents Gate Capital LLP

Regents Gate Capital LLP raised its stake in The Clorox Company (NYSE:CLX - Free Report) by 2,780.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,751 shares of the company's stock after purchasing an additional 46,093 shares during the period. Clorox accounts for about 3.0% of Regents Gate Capital LLP's holdings, making the stock its 15th biggest position. Regents Gate Capital LLP's holdings in Clorox were worth $7,031,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in CLX. Yacktman Asset Management LP lifted its holdings in shares of Clorox by 5.1% during the first quarter. Yacktman Asset Management LP now owns 32,950 shares of the company's stock worth $4,852,000 after purchasing an additional 1,600 shares during the period. Valeo Financial Advisors LLC increased its position in Clorox by 5.5% during the 1st quarter. Valeo Financial Advisors LLC now owns 3,919 shares of the company's stock worth $577,000 after purchasing an additional 206 shares in the last quarter. Liberty One Investment Management LLC increased its position in Clorox by 2.9% during the 1st quarter. Liberty One Investment Management LLC now owns 201,741 shares of the company's stock worth $29,706,000 after purchasing an additional 5,702 shares in the last quarter. Pacific Point Advisors LLC grew its holdings in Clorox by 10.5% in the 1st quarter. Pacific Point Advisors LLC now owns 9,427 shares of the company's stock valued at $1,388,000 after buying an additional 894 shares during the period. Finally, Viewpoint Capital Management LLC grew its holdings in Clorox by 3.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 9,985 shares of the company's stock valued at $1,470,000 after buying an additional 343 shares during the period. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Clorox Stock Performance

CLX traded down $1.29 during trading on Friday, reaching $126.55. 1,376,644 shares of the company were exchanged, compared to its average volume of 1,409,949. The stock has a market cap of $15.60 billion, a P/E ratio of 22.72, a PEG ratio of 3.10 and a beta of 0.51. The firm has a 50 day moving average of $128.52 and a 200 day moving average of $142.83. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The Clorox Company has a 52 week low of $117.35 and a 52 week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same quarter last year, the firm posted $1.71 EPS. The company's revenue was down 8.0% compared to the same quarter last year. On average, sell-side analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on CLX. JPMorgan Chase & Co. reduced their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Jefferies Financial Group reduced their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Barclays reduced their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Finally, UBS Group reduced their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $148.92.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director directly owned 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.57% of the company's stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.